Trial Profile
A retrospective study assessing treatment patterns for acromegaly in Italy in real world
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2018
Price :
$35
*
At a glance
- Drugs Octreotide (Primary) ; Lanreotide; Pegvisomant
- Indications Acromegaly
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2018 New trial record
- 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society